4D Molecular Therapeutics (FDMT) AGM 2026 summary

Opening remarks and agenda

• The meeting was held virtually to enhance participation, communication, and cost savings for stockholders and the company.

• Attendees were introduced to the management team, board members, Inspector of Election, and independent auditor.

• Rules of conduct and the meeting agenda were made available to participants upon joining.

Shareholder proposals

• Three proposals were presented: election of three Class III directors until 2029, ratification of the independent auditor for 2026, and advisory approval of executive compensation.

• No advance notice for director nominations was received, closing nominations.

Overview of voting outcomes

• All three proposals were approved: election of directors, ratification of PricewaterhouseCoopers as auditor, and advisory approval of executive compensation.

• Full vote tallies will be published in a Form 8-K filed with the SEC within four business days.